Ikena Oncology (IKNA) Q1 2025 earnings summary

Executive summary

• Entered into a merger agreement with Inmagene Biopharmaceuticals in December 2024; closing expected mid-2025, subject to shareholder approval and other conditions.

• Discontinued development of IK-930 and prioritized IK-595; continued divestiture of non-core assets and IP.

• Net loss for Q1 2025 was $8.6 million, a 47% improvement year-over-year due to restructuring and reduced R&D spend.

• Cash, cash equivalents, and marketable securities totaled $114.1 million as of March 31, 2025.

• Company’s future operations are highly dependent on successful completion of the merger or another strategic transaction.

Financial highlights

• Q1 2025 net loss: $8.6 million, compared to $16.1 million in Q1 2024.

• Operating expenses decreased 41% year-over-year to $10.8 million, driven by lower R&D and restructuring costs.

• R&D expenses fell 61% to $3.7 million, reflecting program discontinuations and headcount reductions.

• General and administrative expenses decreased 6% to $5.6 million.

• Restructuring and other charges were $1.4 million, down from $2.6 million in Q1 2024.

• Investment income was $1.4 million, down from $2.1 million in Q1 2024 due to lower yields and balances.

Outlook and guidance

• Merger with Inmagene and related $75 million financing expected to close mid-2025; future operations depend on this outcome.

• If the merger is not completed, the board may pursue dissolution and liquidation.

• Current cash position expected to fund operations for at least 12 months if the merger is not consummated.